Amoeba Sa · EURONEXT:ALMIB
Amoeba Sa — Non-Deal Roadshow (December 2023)
28 slides from Amoeba Sa's roadshow presentation, December 2023
Slide 1: Roadshow Presentation December 2023
ROADSHOW PRESENTATION 2023 DECEMBER 2023
Slide 2: Disclaimer
DISCLAIMER References herein to this presentation (the “Presentation”) shall mean and include this document, any oral presentation accompanying this document provided by Amoeba SA (the “Company”), any question and answer session following that oral presentation and any further information that may b
Slide 3: Amoeba's 2022 Valuation
MARKET CAP AMOEBA’S 2022 VALUATION Submission of Market Cap R&D stage an AMM dossier Commercialization 200 M€ Agrauxine * 100% / € 45M Biotalys * 0% / Outsourcing 100 M € Antofénol Amoéba * 13% / € 53 M * 13% / € 23 M 50 M € Maturity * Functional plant / investment
Slide 4: Amoeba's Positioning
AMOEBA’S POSITIONING Strawberry Cucumber Tomato Rice App. € 1000 M Vines Vegetables Potato Arboricultures and others € 800M € 600M € 250M Banana (powdery and downy App. € 100 M mildew) App. € 500 M Current trials on vines (Botrytis) Wheat Soybeans € 2 400M € 2 100M Global Market Volume : € 7 750 Mds
Slide 5: Biocide, a Valuable Asset of Amoeba
BIOCIDE, A VALUABLE ASSET OF AMOEBA The first biological biocide approved for industrial water treatment • A patented innovation in a sector that has been stagnant for 50 years • December 2022 : Approval from US EPA for use in closed cooling systems in the USA. $ 200 M Per year of achievable market
Slide 6: Projection 2024
PROJECTION 2024 To guarantee the emergence of a future French world leader in biocontrol Contribute to the creation of a biocontrol industrial network in France Thanks to our vision and mission Ensuring a sustainable future by Develop a scientific and industrial offering biological alternatives that
Slide 7: Amoeba Presentation
: AMOEBA PRESENTATION a _ amoéba
Slide 8: About Amoeba
ABOUT AMOEBA Amoéba is an industrial biotech in pre-commercialization that provides microbiological solutions for the treatment of natural key resources. Scientific maturity Regulatory maturity 10 years of R&D Europe : Recommendation for approval by Austria announced in April 2022 9 scientific publi
Slide 9: Amoeba Key Figures
AMOEBA KEY FIGURES 25 Millions of euros invested in R&D since 2010 28 Employees in France 1 Industrial expertise centre dedicated to industrial research and development
Slide 10: Comité de Direction Governance
COMITE DE DIRECTION GOVERNANCE Benoit Villers Fabrice Plasson Valérie Filiatre Jean-Luc Souche President Founder and Administrator Administrator Administrator Managing Director & Expert in life science and biologies Expert in business administration Specialist in plant protection Board Member at Nic
Slide 11: Comité de Direction
COMITE DE DIRECTORS BOARD OF DIRECTION Jean-François Doucet General Deputy Expert in finance Jean-Baptiste Eberst Sandrine Troussieux Hervé Testeil Regulatory affairs Director Scientific Director Industrial Director Expert in regulatory affairs Dr. in Sciences, specialized in Industrial expert in ph
Slide 12: Financial Informations
2 - FINANCIAL INFORMATIONS 4
Slide 13: Financing and Shareholding
FINANCING AND SHAREHOLDING Distribution of € 13.2 M Raised during the IPO in July 2015 shareholding € 14.7 M Raised in 2016 by private placement 5% Financing agreement with the European €5M Investment Bank (EIB) in 2017 € 32 M OCAPI with Nice & Green between 2018 and 2022 95% €6M Other funds raised,
Slide 14: Financial Situation
FINANCIAL SITUATION SITUATION FINANCIERE BURN RATE EIB DEBT Refunded in June 2022 2021 2022 2021 2022 € 370 K € 390 K € 6,1 M €0M EQUITY CASHFLOW 2021 2022 2021 2022 € 0,2 M € 8,2 M € 7,3 M € 5,5 M
Slide 15: Biocontrol
3 BIOCONTROL
Slide 16: État de l'art – Biocontrôle
ETAT DE L’ART – BIOCONTROLE CONTEXT European objectives towards CURRENT ISSUES biocontrol 78% reduction of insects between 1989 and 2013 : impact on biodiversity 25% Organic farming crops in Europe by 2030 46% of the foodstuffs analyzed by EFSA are contaminated 50% Reduction of plant by pesticide re
Slide 17: Our Product
OUR PRODUCT Amoéba's expertise at the service of a new era in plant protection Why AXPERA ? • Expert / Expertise • Era (new era in plant protection through effective and safe biocontrol) • AXP : reminder of our experimental formulations (AXP12, AXP13, AXP17) • Values of innovation, performance, resp
Slide 18: Our Solution
OUR SOLUTION A 100% natural biofongicide 90% Effectiveness in climatic chambers on 50 à 95% mildew and Effectiveness in rusts field 2022 (FR) – Untreated (downy mildew) 2022 (FR) – Amoéba treatment (downy mildew) Read more about Amoeba 300 180 +15 < partners Countries Trials by Amoéba Trials by arou
Slide 19: Value Proposition
VALUE PROPOSITION Facilitating the transition from conventional to organic agriculture Conventional Organic Substitutes market market Thanks to our solution : • A unique dual mode of action (elicitor and fungicide) • A wide spectrum of activity (vineyards, vegetables, potatoes, cereals...) • A good
Slide 20: Key Factors of Success
KEY FACTORS OF SUCCESS An innovative and unique product An active substance recommended for from a class of microorganisms never approval by the Rapporteur Member used before in agriculture: amoebas State (Austria) and approved by US EPA A product with no hazard class and a low risk profile A produc
Slide 21: Industrialization
4 INDUSTRIALIZATION
Slide 22: Industrialization
INDUSTRIALIZATION Chassieu Industrial R&D Center 2 x 500 L Production capacity of bioreactors 500 KG of active substance produced per year
Slide 23: Production Site Expansion Project
PRODUCTION SITE EXPANSION PROJECT Creation of a new duplicable factory in Cavaillon Biocontrol production line 23 M € Of investments surface area, including 2000m2 entirely dedicated to 3000 m2 production 40 T of additional active substance, up to 80 T in case of extension hectares treated, up to 20
Slide 24: A Site with the Parc+ Label
A SITE WITH THE PARC+ LABEL A responsible industrial approach at the heart of a dedicated park • Business park dedicated to naturalness • Preservation and enhancement of the landscape, natural resources and local quality of life • Installation of photovoltaic panels on 60% of the roofs • Recycling o
Slide 25: An Optimisation Project in Several Phases
AN OPTIMISATION PROJECT IN SEVERAL PHASES NOE – Chassieu (Existing line) Bioreactors : 2 x 500 L 5 années of maturity of process developments 500 KG of active substance produced per year NOE – Chassieu USIBIAM – Cavaillon (Production line) Bioreactor : 1600L / day Bioréacteurs : 4 x 5000 L Scale-up
Slide 26: Amoeba's Strategy 2024-2026
TAM 12 MDSSTRATEGY AMOEBA’S EUROS 2024-2026 A volume and profitability strategy 40 tons of AS/year = 100 000 hectares treated Vines Lettuce Tomato Aromatic herbs (2 771 000 hectares) (500 000 hectares) (280 000 hectares) (30 000 hectares) Price/ha Price/ha Price/ha Price/ha 50 € 100 € 100 € 250 € KO
Slide 27: Project Financing
ETAT DE L’ART AMOEBA’S – BIOCONTROLE PROJECT FINANCING FINANCING PLAN Finding a balance between € 45 M equity and banking required for the realization of the € 9 M by Nice & Green project € 5,9 M by BPI FRANCE € 23 M Dedicated to the factory construction € 22 M Dedicated to operating expenses over 2
Slide 28: Social Media, Website, Contact
Social Media Website Contact @AmoebaNature amoeba-nature.com [email protected] DECEMBER 2023